Infektionen und Multiple Sklerose

Zusammenfassung

In der Studienliteratur nehmen die Ursachen, Bedingungen und Folgen von Infektionen bei Patienten mit einer Multiplen Sklerose (MS) nicht den Platz ein, der ihnen von der Alltagsrelevanz her zustünde. Gerade Harnwegsinfekte und vor allem Pneumonien tragen erheblich zu Krankenhauseinweisungen, Morbidität und Mortalität bei. In dieser Übersicht werden die aktuellen Erkenntnisse zu den Infektionskrankheiten einschließlich SARS-CoV-2 bei der MS zusammengefasst. Dabei geht es um drei Fragestellungen: Beeinflussen Infektionen das MS-Risiko? Wirken sich Infektionen auf die Krankheitsaktivität bei der MS aus? Welche Effekte haben die verschiedenen immunmodulatorischen MS-Therapien auf das Risiko und den Verlauf von Infektionskrankheiten? Um die Beratung und Versorgung der MS-Patienten zu verbessern, werden die Studienlage und aktuelle Empfehlungen überprüft und erörtert, was im Behandlungsalltag zu beachten ist.

Abstract

In the literature, causes, conditions, and consequences of infections in patients with multiple sclerosis (MS) have not received the attention they deserve in terms of the daily routine. In particular, urinary tract infections and especially pneumonia contribute significantly to hospitalizations, morbidity, and mortality. This review summarizes the current evidence on infectious diseases, including SARS-CoV-2, of multiple sclerosis (MS) patients. Three questions will be addressed: Do infections affect the risk for MS? Do infections affect the disease activity in MS? What are the effects of various immunomodulatory MS therapies on the infectious disease risk and disease progression? To improve primary care of MS patients, the study situation and current recommendations will be reviewed. Factors that need to be taken into consideration in daily treatment will be discussed.

Schlüsselwörter

Infektionen - Multiple Sklerose - Systemischer Überblick - immunmodulatorische MS Therapie

Keywords

infections - multiple sclerosis - systemic overview - immunomodulatory MS therapies - infectiology

Publikationsverlauf

Eingereicht: 19. August 2023

Angenommen nach Revision: 06. März 2024

Artikel online veröffentlicht:
08. Mai 2024

• Literatur

• 1 Goodin DS. The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities. BMC Neurol 2016; 16: 56 DOI: 10.1186/s12883-016-0575-6.
• 2 Guerrero-García JJ, Carrera-Quintanar L, López-Roa RI. et al. Multiple Sclerosis and Obesity: Possible Roles of Adipokines. Mediators Inflamm 2016; 2016: 4036232 DOI: 10.1155/2016/4036232.
• 3 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504-513 DOI: 10.1002/ana.21141.
• 4 Pugliatti M, Harbo HF, Holmøy T. et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008; 188: 34-40 DOI: 10.1111/j.1600-0404.2008.01029.x.
• 5 Amato MP, Derfuss T, Hemmer B. et al. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Mult Scler 2018; 24: 590-603 DOI: 10.1177/1352458516686847.
• 6 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61: 288-299 DOI: 10.1002/ana.21117.
• 7 Marrie RA, Elliott L, Marriott J. et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015; 85: 240-247 DOI: 10.1212/WNL.0000000000001718.
• 8 Marrie RA, Elliott L, Marriott J. et al. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015; 84: 350-358 DOI: 10.1212/WNL.0000000000001187.
• 9 Salter A, Fox RJ, Newsome SD. et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol 2021; 78: 699-708 DOI: 10.1001/jamaneurol.2021.0688.
• 10 Adamczyk-Sowa M, Nowak-Kiczmer M, Jaroszewicz J. et al. Immunosenescence and multiple sclerosis. Neurol Neurochir Pol 2022; 56: 220-227 DOI: 10.5603/PJNNS.a2022.0045.
• 11 Bachmann P, Frahm N, Debus JL. et al. Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics 2022; 14: 592 DOI: 10.3390/pharmaceutics14030592.
• 12 Cauchi M, Willis M, Andrews A. et al Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Pract Neurol 2022; practneurol-2022-003370 DOI: 10.1136/practneurol-2022-003370.
• 13 Frahm N, Hecker M, Zettl UK. Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opin Drug Saf 2020; 19: 139-145 DOI: 10.1080/14740338.2020.1720646.
• 14 Persson R, Lee S, Ulcickas Yood M. et al. Infections in patients diagnosed with multiple sclerosis: A multi-database study. Mult Scler Relat Disord 2020; 41: 101982 DOI: 10.1016/j.msard.2020.101982.
• 15 Papeix C, Donze C, Lebrun-Frénay C. et al. Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2021; 177: 980-994 DOI: 10.1016/j.neurol.2021.04.011.
• 16 Marrodan M, Bensi C, Pappolla A. et al. Disease activity impacts disability progression in primary progressive multiple sclerosis. Mult Scler Relat Disord 2020; 39: 101892 DOI: 10.1016/j.msard.2019.101892.
• 17 Monschein T, Zrzavy T, Löbermann M. et al. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations]. Nervenarzt 2021; 92: 1276-1282 DOI: 10.1007/s00115-021-01155-4.
• 18 Mentis A-FA, Dardiotis E, Grigoriadis N. et al. Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol Neurobiol 2017; 54: 3911-3923 DOI: 10.1007/s12035-017-0530-6.
• 19 Mentis A-FA, Dardiotis E, Grigoriadis N. et al. Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation. Acta Neurol Scand 2017; 136: 606-616 DOI: 10.1111/ane.12775.
• 20 Koga M, Yuki N, Takahashi M. et al. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher’s syndromes. J Neuroimmunol 1998; 81: 138-143 DOI: 10.1016/s0165-5728(97)00168-9.
• 21 van Doorn PA, Van den Bergh PYK, Hadden RDM. et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol 2023; 30: 3646-3674 DOI: 10.1111/ene.16073.
• 22 Wouk J, Rechenchoski DZ, Rodrigues BCD. et al. Viral infections and their relationship to neurological disorders. Arch Virol 2021; 166: 733-753 DOI: 10.1007/s00705-021-04959-6.
• 23 Bjornevik K, Cortese M, Healy BC. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022; 375: 296-301 DOI: 10.1126/science.abj8222.
• 24 Lanz TV, Brewer RC, Ho PP. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 2022; 603: 321-327 DOI: 10.1038/s41586-022-04432-7.
• 25 Pakpoor J, Disanto G, Gerber JE. et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler 2013; 19: 162-166 DOI: 10.1177/1352458512449682.
• 26 Loosen SH, Doege C, Meuth SG. et al. Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: Results from a cohort study of 32,116 outpatients in Germany. Front Immunol 2022; 13: 937583 DOI: 10.3389/fimmu.2022.937583.
• 27 Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol 2023; 21: 51-64 DOI: 10.1038/s41579-022-00770-5.
• 28 Andersen O, Lygner PE, Bergström T. et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993; 240: 417-422 DOI: 10.1007/BF00867354.
• 29 Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36: S25-S28 DOI: 10.1002/ana.410360709.
• 30 Edwards S, Zvartau M, Clarke H. et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 736-741 DOI: 10.1136/jnnp.64.6.736.
• 31 Buljevac D, Flach HZ, Hop WCJ. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-960 DOI: 10.1093/brain/awf098.
• 32 Brütting C, Emmer A, Kornhuber M. et al. A survey of endogenous retrovirus (ERV) sequences in the vicinity of multiple sclerosis (MS)-associated single nucleotide polymorphisms (SNPs). Mol Biol Rep 2016; 43: 827-836 DOI: 10.1007/s11033-016-4004-0.
• 33 Rutschmann OT, McCrory DC, Matchar DB. et al. Immunization and MS: a summary of published evidence and recommendations. Neurology 2002; 59: 1837-1843 DOI: 10.1212/wnl.59.12.1837.
• 34 Oikonen M, Laaksonen M, Aalto V. et al. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 2011; 17: 672-680 DOI: 10.1177/1352458510394397.
• 35 Frohman TC, Davis SL, Beh S. et al. Uhthoff’s phenomena in MS – clinical features and pathophysiology. Nat Rev Neurol 2013; 9: 535-540 DOI: 10.1038/nrneurol.2013.98.
• 36 Nelson RE, Xie Y, DuVall SL. et al. Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans. Int J MS Care 2015; 17: 221-230 DOI: 10.7224/1537-2073.2014-035.
• 37 Wijnands JM, Kingwell E, Zhu F. et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 2017; 23: 1506-1516 DOI: 10.1177/1352458516681198.
• 38 Javed A, Khan O. Acute disseminated encephalomyelitis. Handb Clin Neurol 2014; 123: 705-717 DOI: 10.1016/B978-0-444-53488-0.00035-3.
• 39 Paolilo RB, Deiva K, Neuteboom R. et al. Acute Disseminated Encephalomyelitis: Current Perspectives. Children (Basel) 2020; 7: 210 DOI: 10.3390/children7110210.
• 40 Marsool MDM, Prajjwal P, Inban P. et al. Adult-onset acute disseminated encephalomyelitis: a rare case report in a 26-year-old female and review of literature. Ann Med Surg (Lond) 2023; 85: 5242-5245 DOI: 10.1097/MS9.0000000000001239.
• 41 Banwell B, Bennett JL, Marignier R. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268-282 DOI: 10.1016/S1474-4422(22)00431-8.
• 42 Sechi E, Cacciaguerra L, Chen JJ. et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 2022; 13: 885218 DOI: 10.3389/fneur.2022.885218.
• 43 Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 2023; 14: 1260358 DOI: 10.3389/fneur.2023.1260358.
• 44 Zhong X, Zhou Y, Lu T. et al. Infections in neuromyelitis optica spectrum disorder. J Clin Neurosci 2018; 47: 14-19 DOI: 10.1016/j.jocn.2017.10.005.
• 45 Tur C, Dubessy A-L, Otero-Romero S. et al. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Mult Scler 2022; 28: 1424-1456 DOI: 10.1177/13524585211069068.
• 46 Castelo-Branco A, Chiesa F, Conte S. et al. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult Scler Relat Disord 2020; 45: 102420 DOI: 10.1016/j.msard.2020.102420.
• 47 Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 2013; 20: 1153-1160 DOI: 10.1111/ene.12130.
• 48 Ghaderi S, Berg-Hansen P, Bakken IJ. et al. Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway. Eur J Epidemiol 2020; 35: 355-362 DOI: 10.1007/s10654-019-00595-2.
• 49 De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159: 51-53 DOI: 10.1016/s0022-510x(98)00139-7.
• 50 Magyari M, Sorensen PS. Comorbidity in Multiple Sclerosis. Front Neurol 2020; 11: 851 DOI: 10.3389/fneur.2020.00851.
• 51 Capkun G, Dahlke F, Lahoz R. et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 2015; 4: 546-554 DOI: 10.1016/j.msard.2015.08.005.
• 52 Harding K, Zhu F, Alotaibi M. et al. Multiple cause of death analysis in multiple sclerosis: A population-based study. Neurology 2020; 94: e820-e829 DOI: 10.1212/WNL.0000000000008907.
• 53 Oksbjerg NR, Nielsen SD, Blinkenberg M. et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord 2021; 52: 102988 DOI: 10.1016/j.msard.2021.102988.
• 54 de Sèze M, Ruffion A, Denys P. et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13: 915-928 DOI: 10.1177/1352458506075651.
• 55 Jick SS, Li L, Falcone GJ. et al. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol 2015; 262: 2033-2041 DOI: 10.1007/s00415-015-7796-2.
• 56 Gallien P, Robineau S, Nicolas B. et al. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil 1998; 79: 255-257 DOI: 10.1016/s0003-9993(98)90003-x.
• 57 Li V, Barker N, Curtis C. et al. The prevention and management of hospital admissions for urinary tract infection in patients with multiple sclerosis. Mult Scler Relat Disord 2020; 45: 102432 DOI: 10.1016/j.msard.2020.102432.
• 58 Phé V, Pakzad M, Curtis C. et al. Urinary tract infections in multiple sclerosis. Mult Scler 2016; 22: 855-861 DOI: 10.1177/1352458516633903.
• 59 Shigemura K, Takase R, Osawa K. et al. Emergence and prevention measures for multidrug resistant Pseudomonas aeruginosa in catheter-associated urinary tract infection in spinal cord injury patients. Spinal Cord 2015; 53: 70-74 DOI: 10.1038/sc.2014.154.
• 60 Jahromi MS, Mure A, Gomez CS. UTIs in patients with neurogenic bladder. Curr Urol Rep 2014; 15: 433 DOI: 10.1007/s11934-014-0433-2.
• 61 Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009; 59: e329-e338 DOI: 10.3399/bjgp09X472629.
• 62 Tzelepis GE, McCool FD. Respiratory dysfunction in multiple sclerosis. Respir Med 2015; 109: 671-679 DOI: 10.1016/j.rmed.2015.01.018.
• 63 Pletz MW, Rohde GG, Welte T. et al Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Res 2016; 5 F1000 Faculty Rev-300 DOI: 10.12688/f1000research.7657.1.
• 64 Ewig S, Kolditz M, Pletz M. et al. [Management of Adult Community-Acquired Pneumonia and Prevention – Update 2021 – Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (ÖGP), the Austrian Society for Infectious and Tropical Diseases (ÖGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie 2021; 75: 665-729 DOI: 10.1055/a-1497-0693.
• 65 Dalhoff K, Abele-Horn M, Andreas S. et al. [Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia – Update 2017 – S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology]. Pneumologie 2018; 72: 15-63 DOI: 10.1055/s-0043-121734.
• 66 Ramirez JA, Musher DM, Evans SE. et al. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest 2020; 158: 1896-1911 DOI: 10.1016/j.chest.2020.05.598.
• 67 Stastna D, Menkyova I, Drahota J. et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Mult Scler Relat Disord 2021; 54: 103104 DOI: 10.1016/j.msard.2021.103104.
• 68 Brand JS, Smith KA, Piehl F. et al. Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study. Brain Behav Immun Health 2022; 22: 100470 DOI: 10.1016/j.bbih.2022.100470.
• 69 Knapp R, Hardtstock F, Krieger J. et al. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study. Mult Scler Relat Disord 2022; 68: 104245 DOI: 10.1016/j.msard.2022.104245.
• 70 Luna G, Alping P, Burman J. et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2020; 77: 184-191 DOI: 10.1001/jamaneurol.2019.3365.
• 71 Hauer L, Perneczky J, Sellner J. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol 2021; 268: 4066-4077 DOI: 10.1007/s00415-020-10107-y.
• 72 Rostami Mansoor S, Ghasemi-Kasman M. Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients. J Med Virol 2021; 93: 1314-1319 DOI: 10.1002/jmv.26593.
• 73 Winkelmann A, Loebermann M, Reisinger EC. et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12: 217-233 DOI: 10.1038/nrneurol.2016.21.
• 74 Winkelmann A, Loebermann M, Barnett M. et al. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022; 18: 289-306 DOI: 10.1038/s41582-022-00646-5.
• 75 Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab – a case for better preventive strategies. BMC Neurol 2017; 17: 65 DOI: 10.1186/s12883-017-0848-8.
• 76 Wray S, Havrdova E, Snydman DR. et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler 2019; 25: 1605-1617 DOI: 10.1177/1352458518796675.
• 77 Ford CC, Johnson KP, Lisak RP. et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309-320 DOI: 10.1191/135248506ms1318oa.
• 78 Ebers GC. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504
• 79 Calabresi PA, Kieseier BC, Arnold DL. et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13: 657-665 DOI: 10.1016/S1474-4422(14)70068-7.
• 80 Fox RJ, Chan A, Gold R. et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract 2016; 6: 220-229 DOI: 10.1212/CPJ.0000000000000238.
• 81 Warnke C, Dehmel T, Ramanujam R. et al. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology 2014; 83: 2153-2157 DOI: 10.1212/WNL.0000000000001049.
• 82 Berger JR, Cree BA, Greenberg B. et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 2018; 90: e1815-e1821 DOI: 10.1212/WNL.0000000000005529.
• 83 Gold R, Arnold DL, Bar-Or A. et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler 2022; 28: 801-816 DOI: 10.1177/13524585211037909.
• 84 Coles AJ, Twyman CL, Arnold DL. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839 DOI: 10.1016/S0140-6736(12)61768-1.
• 85 Cohen JA, Coles AJ, Arnold DL. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828 DOI: 10.1016/S0140-6736(12)61769-3.
• 86 Leist T, Cook S, Comi G. et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord 2020; 46: 102572 DOI: 10.1016/j.msard.2020.102572.
• 87 Cook S, Giovannoni G, Leist T. et al. Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data (1656). Neurology 2020; 94: 1656
• 88 Confavreux C, O’Connor P, Comi G. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 247-256 DOI: 10.1016/S1474-4422(13)70308-9.
• 89 Foley J, Carrillo-Infante C, Smith J. et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord 2020; 39: 101863 DOI: 10.1016/j.msard.2019.101863.
• 90 Butzkueven H, Kappos L, Wiendl H. et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91: 660-668 DOI: 10.1136/jnnp-2019-322326.
• 91 Hauser SL, Bar-Or A, Cohen JA. et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020; 383: 546-557 DOI: 10.1056/NEJMoa1917246.
• 92 Kappos L, Radue E-W, O’Connor P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401 DOI: 10.1056/NEJMoa0909494.
• 93 Cohen JA, Barkhof F, Comi G. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415 DOI: 10.1056/NEJMoa0907839.
• 94 Lublin F, Miller DH, Freedman MS. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075-1084 DOI: 10.1016/S0140-6736(15)01314-8.
• 95 Fox RJ, Miller DH, Phillips JT. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097 DOI: 10.1056/NEJMoa1206328.
• 96 Hauser SL, Bar-Or A, Comi G. et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376: 221-234 DOI: 10.1056/NEJMoa1601277.
• 97 Kappos L, Cohen J, Collins W. et al. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Mult Scler Relat Disord 2014; 3: 494-504 DOI: 10.1016/j.msard.2014.03.002.
• 98 Giovannoni G, Comi G, Cook S. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426 DOI: 10.1056/NEJMoa0902533.
• 99 Arvin AM, Wolinsky JS, Kappos L. et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72: 31-39 DOI: 10.1001/jamaneurol.2014.3065.
• 100 O’Connor P, Comi G, Freedman MS. et al. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology 2016; 86: 920-930 DOI: 10.1212/WNL.0000000000002441.
• 101 Kappos L, Bar-Or A, Cree BAC. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391: 1263-1273 DOI: 10.1016/S0140-6736(18)30475-6.
• 102 Pfender N, Jelcic I, Linnebank M. et al. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Neurology 2015; 84: 2377-2378 DOI: 10.1212/WNL.0000000000001659.
• 103 Ayers MC, Conway DS. A case of presumed herpes keratouveitis in a patient treated with fingolimod. Mult Scler J Exp Transl Clin 2016; 2: 2055217316652907 DOI: 10.1177/2055217316652907.
• 104 Hauser SL, Kappos L, Arnold DL. et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 2020; 95: e1854-e1867 DOI: 10.1212/WNL.0000000000010376.
• 105 Pei S-N, Chen C-H, Lee C-M. et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-262 DOI: 10.1007/s00277-009-0806-7.
• 106 Evens AM, Jovanovic BD, Su Y-C. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180 DOI: 10.1093/annonc/mdq583.
• 107 Ciardi MR, Iannetta M, Zingaropoli MA. et al. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis 2019; 6: ofy356 DOI: 10.1093/ofid/ofy356.
• 108 Gold R, Kappos L, Arnold DL. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107 DOI: 10.1056/NEJMoa1114287.
• 109 Durrieu G, Dardonville Q, Clanet M. et al. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol 2019; 33: 125-126 DOI: 10.1111/fcp.12394.
• 110 Rolfes L, Lokhorst B, Samijn J. et al. Cervical dysplasia associated with the use of natalizumab. Neth J Med 2013; 71: 494-495
• 111 Willis MD, Harding KE, Pickersgill TP. et al. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler 2016; 22: 1215-1223 DOI: 10.1177/1352458515614092.
• 112 Triplett J, Kermode AG, Corbett A. et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler 2019; 25: 1547-1550 DOI: 10.1177/1352458518807088.
• 113 Novartis. Gilenya^® Checkliste für Ärzte Version 13.3; Genehmigung 06 /2021. Stand 1/2022; Artikelnummer 1080565. Im Internet: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/EducationMaterial/Anlagen/fingolimod-gilenya-aerzte3.pdf Stand: 23.11.2023
• 114 Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 2018; 17: 467-480 DOI: 10.1016/S1474-4422(18)30040-1.
• 115 Jordan AL, Yang J, Fisher CJ. et al. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 2022; 28: 7-15 DOI: 10.1177/1352458520949158.
• 116 Anton R, Haas M, Arlett P. et al. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators’ perspective. Clin Pharmacol Ther 2017; 102: 283-289 DOI: 10.1002/cpt.604.
• 117 Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord 2016; 9: 158-162 DOI: 10.1016/j.msard.2016.07.015.
• 118 Gundacker ND, Jordan SJ, Jones BA. et al. Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab. Open Forum Infect Dis 2016; 3: ofw038 DOI: 10.1093/ofid/ofw038.
• 119 Valenzuela RM, Pula JH, Garwacki D. et al. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci 2014; 340: 109-111 DOI: 10.1016/j.jns.2014.03.007.
• 120 Tully T, Barkley A, Silber E. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod. Neurology 2015; 84: 1999-2001 DOI: 10.1212/WNL.0000000000001556.
• 121 Enriquez-Marulanda A, Valderrama-Chaparro J, Parrado L. et al. Cerebral toxoplasmosis in an MS patient receiving Fingolimod. Mult Scler Relat Disord 2017; 18: 106-108 DOI: 10.1016/j.msard.2017.05.004.
• 122 Clerico M, De Mercanti S, Artusi CA. et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler 2017; 23: 874-876 DOI: 10.1177/1352458516688350.
• 123 Boyle S, Olive G, Townell N. et al. Legionella longbeachae pneumonia as a complication of alemtuzumab therapy. J Clin Neurosci 2017; 46: 67-69 DOI: 10.1016/j.jocn.2017.08.051.
• 124 Penkert H, Delbridge C, Wantia N. et al. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis. JAMA Neurol 2016; 73: 757-759 DOI: 10.1001/jamaneurol.2016.0146.
• 125 Russo CV, Saccà F, Paternoster M. et al. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler 2020; 26: 123-126 DOI: 10.1177/1352458518813110.
• 126 Rau D, Lang M, Harth A. et al. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis – Report of Two Cases. Int J Mol Sci 2015; 16: 14669-14676 DOI: 10.3390/ijms160714669.
• 127 Tecellioglu M, Kamisli O, Kamisli S. et al. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy. Mult Scler Relat Disord 2019; 27: 409-411 DOI: 10.1016/j.msard.2018.11.025.
• 128 Ruggieri S, Logoteta A, Martini G. et al. Listeria monocytogenes-Induced Rhombencephalitis in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate. JAMA Neurol 2018; 75: 762-763 DOI: 10.1001/jamaneurol.2018.0368.
• 129 Schippling S, Kempf C, Büchele F. et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 2013; 74: 622-626 DOI: 10.1002/ana.23973.
• 130 Agnihotri SP, Dang X, Carter JL. et al. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology 2014; 83: 727-732 DOI: 10.1212/WNL.0000000000000713.
• 131 Hampel A, Solbach P, Cornberg M. et al. [Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 578-583 DOI: 10.1007/s00103-016-2333-8.
• 132 Stadtmüller S, Schröder J, Ehlers S. Estimating and Explaining the Prevalence of Tuberculosis for Asylum Seekers Upon Their Arrival in Germany. J Immigr Minor Health 2021; 23: 1187-1192 DOI: 10.1007/s10903-020-01134-y.
• 133 Jack D, Damian D, Nolting A. et al. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Mult Scler Relat Disord 2021; 51: 102929 DOI: 10.1016/j.msard.2021.102929.
• 134 Chaudhry F, Bulka H, Rathnam AS. et al. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci 2020; 418: 117147 DOI: 10.1016/j.jns.2020.117147.
• 135 Parrotta E, Kister I, Charvet L. et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm 2020; 7: e835 DOI: 10.1212/NXI.0000000000000835.
• 136 Möhn N, Konen FF, Pul R. et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020; 9: 4067 DOI: 10.3390/jcm9124067.
• 137 Louapre C, Collongues N, Stankoff B. et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol 2020; 77: 1079-1088 DOI: 10.1001/jamaneurol.2020.2581.
• 138 Sormani MP, De Rossi N, Schiavetti I. et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 2021; 89: 780-789 DOI: 10.1002/ana.26028.
• 139 Reder AT, Centonze D, Naylor ML. et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs 2021; 35: 317-330 DOI: 10.1007/s40263-021-00804-1.
• 140 Smith TE, Madhavan M, Gratch D. et al. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. Mult Scler Relat Disord 2022; 60: 103735 DOI: 10.1016/j.msard.2022.103735.
• 141 Simpson-Yap S, De Brouwer E, Kalincik T. et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology 2021; 97: e1870-e1885 DOI: 10.1212/WNL.0000000000012753.
• 142 Sharifian-Dorche M, Sahraian MA, Fadda G. et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord 2021; 50: 102800 DOI: 10.1016/j.msard.2021.102800.
• 143 Otero-Romero S, Lebrun-Frénay C, Reyes S. et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler 2023; 29: 904-925 DOI: 10.1177/13524585231168043.
• 144 Zettl UK, Rommer PS. New consensus guidelines on vaccination in multiple sclerosis. Nat Rev Neurol 2023; 19: 509-510 DOI: 10.1038/s41582-023-00854-7.
• 145 Wagner N, Assmus F, Arendt G. et al. Impfen bei Immundefizienz. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 494-515 DOI: 10.1007/s00103-019-02905-1.